Fig. 3.

Genetic variation affect MACE and Survival in response to MSC delivery. A) V− patients had 100% survival, VUS had 85% survival, and PV+ had 40% survival (Log-rank (Mantel-Cox) test p = 0.015). Overall, PV+ patient's had a substantial increase in death, transplant, or LVAD risk by 1 year follow-up. B) MACE events differed between groups; V- patients had 0 events, VUS had 7 events, and PV+ had 6 events in 4 patients (Log-rank (Mantel-Cox) test= 0.021). V- = negative for any pathologic variants group (green), VUS = variants of uncertain significance group (orange) PV+ = positive for pathologic/likely pathologic variant group (red). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)